

Evaluating the Impact of Education on Clinician Integration of Guidelines, Real-World Data, and Patient Perspectives on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Tariqa Ackbarali, PhD¹, Cindy Lovelace², Jonathan Strosberg, MD³, Al B. Benson III, MD, FACP, FASCO⁴

1 - PlatformQ Health, LLC, Needham, MA;

2 - Healing NET Foundation, Nashville, TN;

3 - Moffitt Cancer Center, Tampa, FL;

4 - Northwestern University, Chicago, IL


This activity is supported by educational grants from AAA (Advanced Accelerator Applications) and Ipsen.

INTRODUCTION AND METHODOLOGY

Educational Gaps and Program Details




Significant advancements in targeted therapies for somatostatin receptor-positive NETs



SSA for GEP-NETs are allowing for better management of difficult-to-treat tumors



An educational initiative was designed to improve competence in applying these advances and considering patient perspectives in treatment selection




Interventions

A 1-hour CME activity was broadcast live-online in October 2021 and remains on-demand through October 2022 at OMedLive.com.



Module 1:

Focused on real-world and quality-of-life data, and consensus guidelines related to somatostatin analogs (SSA) and peptide receptor radiotherapies (PRRT).



Module 2:

Highlighted patient perspectives based on interviews of real patients with SSA and PRRT experience. This was distributed via social media through the Healing NET Foundation.



Partners

Education: PlatformQ Health, PIM

Collaboration & Advocacy: Healing NET Foundation



Measurements

Questions asked pre-, immediate post-, and 2-months post-activity. Chi Square tests used for statistical analysis.



Al B. Benson III, MD, FACP, FASCO

Professor of Medicine
Associate Director for Cooperative Groups
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL



Jonathan Strosberg, MD

Head, Neuroendocrine Section
Chair, GI Research Program
Moffitt Cancer Center and Research Institute
Tampa, FL

RESULTS

Learner Demographics



391

total learners



69%

MD/NP/PA




22

average years
in practice



66%

target audience
learners*



10.21

average patient
visits weekly

Learner Engagement



175

certificates
awarded



70

slides
downloaded



33:54

average time in
session




740

social media
views

*Target Audience: medical oncologists, endocrinologists, radiation oncologists, nuclear-medicine physicians and technologists, surgical oncologists, interventional radiologists, internists, nurses, nurse practitioners, and physician assistants.


RESULTS

Impact on Clinical Practice



n=48

of learners reported the activities positively impacted their clinical practice



write-in examples were shared

Greater use of
177 Lu-DOTATATE


Better ability to diagnose
and manage NET

Increased understanding of the
scope of emerging therapy for
this group of patients

I plan to change my practice with
increased discussions and shared
decision-making with patients
about choices, safety, and efficacy

RESULTS

Impact on Patient Experiences/Outcomes



n=45

of learners reported the activity positively impacted their patients' experiences or outcomes

Confidence in managing NET

Request to add octreotide LAR on hospital formulary


Patient compliance and following of cases increased

Increased confidence in treatment decision-making

RESULTS


Changes in Knowledge/Competence

Clinical application of PRRTs based on the NETTER-1 trial results



n = 391 pretest, n = 183 posttest
 $P < 0.05$

Selection of first-line treatment for somatostatin receptor-positive NETs based on the CLARINET study results




n = 391 pretest, n = 183 posttest
 $P < 0.05$

RESULTS


Changes in Knowledge/Competence

Selection of second-line therapy considering patient preferences for a limited treatment course and low toxicity



n = 391 pretest, n = 183 posttest
P<0.05


Prophylactic management of patients on PRRT




n = 391 pretest, n = 183 posttest
P<0.05

Provider Insights


Top 3 Challenges Faced Managing a Patient With a NET



Adherence to treatment
schedules



Affording therapy



Patient understanding of
treatment options

n=183



Learn more about the impact of NETs



Assessments revealed the positive impact of live-online education on clinical practice when sharing patient perspectives in the context of clinical updates. Open-ended responses to behavioral impact questions illustrated clear improvements in clinician-reported patient experiences and outcomes, clinical practice management, and knowledge of SSA and PRRT for patients with GEP-NETs.